Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
2019 · The Lancet · 2,820 citations
https://doi.org/10.1016/s0140-6736(19)31149-3
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
67
Papers
5.1K
Citations
20
h-index
33
i10-index
Daniel Lorber is an academic researcher from Group for the Analysis of Development. The author has contributed to research in topics: Diabetes Management and Research & Diabetes Treatment and Management & Metabolism, Diabetes, and Cancer. The author has an h-index of 20, co-authored 57 publications.
https://doi.org/10.1016/s0140-6736(19)31149-3
https://doi.org/10.1016/s0140-6736(19)31150-x
Click to start Chat